Latest Insights in Uncategorized
Barclays Entrepreneur of the Year and Beyond Biotech podcast
On Thursday 6 November Llusern CEO Dr Emma Hayhurst and Managing Director Martyn Lewis attended the Barclays Entrepreneur of the…
New antibiogram data shows Lodestar covers 96% of UTI pathogens
New NHS study data shows that 96% of UTIs are caused by only six pathogens, all of which are detected…
A perfect partnership at The Forbury Clinic
The Lodestar DX testing system is designed for detecting pathogens in urine at clinically relevant levels – however it is…
Lodestar DX helps reduce antibiotic use at elderly care home
We’re working with Christadelphian Care Homes to help them triage residents at their always-sunny-in Swansea facility. UTIs in elderly people…
Llusern grabs the limelight at Arab Health 2025
Llusern Scientific exhibited the Lodestar UTI testing system outside Europe for the first time in January this year when the…
Study shows Lodestar DX accurately identifies uropathogens in mixed growth cultures
A new abstract published in JAC-Antimicrobial Resistance demonstrates that the Lodestar DX UTI testing system can ‘accurately identify the common…
Llusern secures pre-Seed investment from DBW
The Development Bank of Wales has taken an equity stake in Cardiff-based Llusern Scientific as part of a substantial six-figure…
Llusern included in NICE early value assessment for UTI testing
Llusern Scientific is delighted to be included as one of the point-of-care technologies being considered by the National Institute for…
Start a conversation with Llusern
Llusern is developing treatment-directing diagnostics for high-volume healthcare challenges, starting with rapid molecular UTI testing. To learn more about the company, the product and the opportunity ahead, speak to the Llusern team.